Successful Progressive Challenge after a Cutaneous Reaction to Imatinib Mesylate (Gleevec): A Case Report and Review of the Literature

Authors: Park, Miguel A.; Volcheck, Gerald W.; Guarderas, Juan C.

Source: Allergy and Asthma Proceedings, Volume 25, Number 5, September-October 2004 , pp. 345-347(3)

Publisher: OceanSide Publications, Inc

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

The use of imatinib mesylate (Gleevec), a selective tyrosine kinase inhibitor, has become the new gold standard for the treatment of chronic myeloid leukemia. Unfortunately, the medication has been commonly associated with mild to severe cutaneous reactions, which has limited its use for some patients. We describe a case of a successful progressive challenge of a patient with a drug-induced exanthem from imatinib mesylate and a review of the literature.

Document Type: Research article

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$39.50 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A